The DOI matches its Crossref record; 208 of the 208 references it cites were found in a registry or an index.
Therapeutic modulators of STAT signalling for human diseases
Open accessAbstract
The signal transducer and activator of transcription (STAT) proteins have important roles in biological processes. The abnormal activation of STAT signalling pathways is also implicated in many human diseases, including cancer, autoimmune diseases, rheumatoid arthritis, asthma and diabetes. Over a decade has passed since the first inhibitor of a STAT protein was reported and efforts to discover modulators of STAT signalling as therapeutics continue. This Review discusses the outcomes of the ongoing drug discovery research endeavours against STAT proteins, provides perspectives on new directions for accelerating the discovery of drug candidates, and highlights the noteworthy candidate therapeutics that have progressed to clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Kunnumakkara, A. B., Nair, S. A., Sung, B., Pandey, M. K., & Aggarwal, B. B. (2009) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-08-0154 · Cited by 118
RetractedKannappan, R., Yadav, V. R., & Aggarwal, B. B. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.158378 · Cited by 64
RetractedSorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Cheng, A.-L., Kang, Y.-K., Chen, Z., Tsao, C.-J., Qin, S., Kim, J. S., Luo, R., Feng, J., Ye, S., Yang, T.-S., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70285-7 · Cited by 5,832
Sorafenib in Advanced Hepatocellular Carcinoma
정, 재. (2008) · Cited by 5,586
Darnell, J. E. (1997) · Science · doi:10.1126/science.277.5332.1630 · Cited by 3,979
The STATs of cancer — new molecular targets come of age
Yu, H., & Jove, R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1275 · Cited by 2,278
Bowman, T., Garcia, R., Turkson, J., & Jove, R. (2000) · Oncogene · doi:10.1038/sj.onc.1203527 · Cited by 1,743
Self-citationMeraz, M. A., White, J. M., Sheehan, K. C. F., Bach, E. A., Rodig, S. J., Dighe, A. S., Kaplan, D. H., Riley, J. K., Greenlund, A. C., Campbell, D., et al. (1996) · Cell · doi:10.1016/s0092-8674(00)81288-x · Cited by 1,656
Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
Kantarjian, H., Shah, N. P., Hochhaus, A., Cortes, J., Shah, S., Ayala, M., Moiraghi, B., Shen, Z., Mayer, J., Pasquini, R., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002315 · Cited by 1,589
The JAK-STAT Pathway at Twenty
Stark, G. R., & Darnell, J. E. (2012) · Immunity · doi:10.1016/j.immuni.2012.03.013 · Cited by 1,517
Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality
Takeda, K., Noguchi, K., Shi, W., Tanaka, T., Matsumoto, M., Yoshida, N., Kishimoto, T., & Akira, S. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.8.3801 · Cited by 1,323
STAT3 Mutations in the Hyper-IgE Syndrome
Holland, S. M., DeLeo, F. R., Elloumi, H. Z., Hsu, A. P., Uzel, G., Brodsky, N., Freeman, A. F., Demidowich, A., Davis, J., Turner, M. L., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa073687 · Cited by 1,221
Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis
Niu, G., Wright, K. L., Huang, M., Song, L., Haura, E., Turkson, J., Zhang, S., Wang, T., Sinibaldi, D., Coppola, D., et al. (2002) · Oncogene · doi:10.1038/sj.onc.1205260 · Cited by 1,207
Self-citationThe role of STATs in transcriptional control and their impact on cellular function
Bromberg, J., & Darnell, J. E. (2000) · Oncogene · doi:10.1038/sj.onc.1203476 · Cited by 1,201
Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells
Wang, T., Niu, G., Kortylewski, M., Burdelya, L., Shain, K., Zhang, S., Bhattacharya, R., Gabrilovich, D., Heller, R., Coppola, D., et al. (2004) · Nature Medicine · doi:10.1038/nm976 · Cited by 1,155
Stattic: a small-molecule inhibitor of STAT3 activation and dimerization
Schust, J., Sperl, B., Hollis, A., Mayer, T. U., & Berg, T. (2006) · Chemistry & Biology · doi:10.1016/j.chembiol.2006.09.018 · Cited by 1,105
Buettner, R., Mora, L. B., & Jove, R. (2002) · PubMed · Cited by 1,040
Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity
Kortylewski, M., Kujawski, M., Wang, T., Wei, S., Zhang, S., Pilon-Thomas, S., Niu, G., Kay, H., Mulé, J., Kerr, W. G., et al. (2005) · Nature Medicine · doi:10.1038/nm1325 · Cited by 1,031
Molecular Mechanisms RegulatinG Th1 Immune Responses
Szabo, S. J., Sullivan, B. M., Peng, S. L., & Glimcher, L. H. (2003) · Annual Review of Immunology · doi:10.1146/annurev.immunol.21.120601.140942 · Cited by 1,019
Requirement of STAT5b for sexual dimorphism of body growth rates and liver gene expression
Udy, G. B., Towers, R. P., Snell, R. G., Wilkins, R. J., Park, S.-H., Ram, P. A., Waxman, D. J., & Davey, H. W. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.14.7239 · Cited by 988
JAKs and STATs in immunity, immunodeficiency, and cancer
O'Shea, J. J., Holland, S. M., & Staudt, L. M. (2013) · New England Journal of Medicine · doi:10.1056/nejmra1202117 · Cited by 927
An Interleukin-4-Induced Transcription Factor: IL-4 Stat
Hou, J., Schindler, U., Henzel, W. J., Ho, T. C., Brasseur, M., & McKnight, S. L. (1994) · Science · doi:10.1126/science.8085155 · Cited by 854
Quintás-Cardama, A., Vaddi, K., Liu, P., Manshouri, T., Li, J., Scherle, P. A., Caulder, E., Wen, X., Li, Y., Waeltz, P., et al. (2010) · Blood · doi:10.1182/blood-2009-04-214957 · Cited by 843
Liu, L., Okada, S., Kong, X.-F., Kreins, A. Y., Cypowyj, S., Abhyankar, A., Toubiana, J., Itan, Y., Audry, M., Nitschke, P., et al. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20110958 · Cited by 797
Somatic STAT3 Mutations in Large Granular Lymphocytic Leukemia
Koskela, H. L. M., Eldfors, S., Ellonen, P., van Adrichem, A. J., Kuusanmäki, H., Andersson, E. I., Lagström, S., Clemente, M. J., Olson, T., Jalkanen, S. E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114885 · Cited by 777
Siddiquee, K., Zhang, S., Guida, W. C., Blaskovich, M. A., Greedy, B., Lawrence, H. R., Yip, M. L. R., Jove, R., McLaughlin, M. M., Lawrence, N. J., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0609757104 · Cited by 736
Self-citationSTAT1 Mutations in Autosomal Dominant Chronic Mucocutaneous Candidiasis
van de Veerdonk, F. L., Plantinga, T. S., Hoischen, A., Smeekens, S. P., Joosten, L. A. B., Gilissen, C., Arts, P., Rosentul, D. C., Carmichael, A. J., Smits-van der Graaf, C. A. A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1100102 · Cited by 666
STAT proteins: novel molecular targets for cancer drug discovery
Turkson, J., & Jove, R. (2000) · Oncogene · doi:10.1038/sj.onc.1204086 · Cited by 643
Self-citationTakeda, K., Kaisho, T., Yoshida, N., Takeda, J., Kishimoto, T., & Akira, S. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1500168 · Cited by 616
Takeda, K., Kaisho, T., Yoshida, N., Takeda, J., Kishimoto, T., & Akira, S. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.9.4652 · Cited by 584
Blaskovich, M. A., Sun, J., Cantor, A. B., Turkson, J., Jove, R., & Sebti, S. M. (2003) · PubMed · Cited by 561
Self-citationThe JAK2 Inhibitor AZD1480 Potently Blocks Stat3 Signaling and Oncogenesis in Solid Tumors
Hedvat, M., Huszar, D., Herrmann, A., Gozgit, J. M., Schroeder, A., Sheehy, A., Buettner, R., Proia, D., Kowolik, C. M., Xin, H., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.10.015 · Cited by 526
Sano, S., Itami, S., Takeda, K., Tarutani, M., Yamaguchi, Y., Miura, H., Yoshikawa, K., Akira, S., & Takeda, J. (1999) · The EMBO Journal · doi:10.1093/emboj/18.17.4657 · Cited by 519
Song, H., Wang, R., Wang, S., & Lin, J. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409894102 · Cited by 504
Biological activity of piceatannol: Leaving the shadow of resveratrol
Piotrowska, H., Kucinska, M., & Murias, M. (2012) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2011.11.001 · Cited by 476
Turkson, J., Ryan, D., Kim, J. S., Zhang, Y., Chen, Z., Haura, E., Laudano, A., Sebti, S., Hamilton, A. D., & Jove, R. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m107527200 · Cited by 448
Self-citationConstitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia.
Shuai, K., Halpern, J., ten Hoeve, J., Rao, X., & Sawyers, C. L. (1996) · PubMed · Cited by 434
Targeting STAT3 in cancer: how successful are we?
Yue, P., & Turkson, J. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780802565791 · Cited by 413
Self-citationThe role of Stat5a and Stat5b in signaling by IL-2 family cytokines
Lin, J.-X., & Leonard, W. J. (2000) · Oncogene · doi:10.1038/sj.onc.1203523 · Cited by 368
Ravandi, F., O'Brien, S., Thomas, D., Faderl, S., Jones, D., Garris, R., Dara, S., Jorgensen, J., Kebriaei, P., Champlin, R., et al. (2010) · Blood · doi:10.1182/blood-2009-12-261586 · Cited by 348
Functional Roles of STAT Family Proteins: Lessons from Knockout Mice
Akira, S. (1999) · STEM CELLS · doi:10.1002/stem.170138 · Cited by 348
Zhang, X., Yue, P., Page, B. D. G., Li, T., Zhao, W., Namanja, A. T., Paladino, D., Zhao, J., Chen, Y., Gunning, P. T., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1121606109 · Cited by 344
Self-citationMechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs)
Duensing, A., Medeiros, F., McConarty, B., Joseph, N. E., Panigrahy, D., Singer, S., Fletcher, C. D., Demetri, G. D., & Fletcher, J. A. (2004) · Oncogene · doi:10.1038/sj.onc.1207525 · Cited by 343
Stat5b Is Essential for Natural Killer Cell–mediated Proliferation and Cytolytic Activity
Imada, K., Bloom, E. T., Nakajima, H., Horvath-Arcidiacono, J. A., Udy, G. B., Davey, H. W., & Leonard, W. J. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.11.2067 · Cited by 325
Resveratrol addiction: To die or not to die
Shakibaei, M., Harikumar, K. B., & Aggarwal, B. B. (2009) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.200800148 · Cited by 316
Sen, M., Thomas, S. M., Kim, S., Yeh, J. I., Ferris, R. L., Johnson, J. T., Duvvuri, U., Lee, J., Sahu, N., Joyce, S., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0191 · Cited by 313
Niu, G., Heller, R. F., Catlett-Falcone, R., Coppola, D., Jaroszeski, M. J., Dalton, W. S., Jove, R., & Yu, H. (1999) · PubMed · Cited by 312
Shin, D.-S., Kim, H.-N., Shin, K. D., Yoon, Y. J., Kim, S.-J., Han, D. C., & Kwon, B.-M. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2575 · Cited by 309
Validating Stat3 in cancer therapy
Darnell, J. E. (2005) · Nature Medicine · doi:10.1038/nm0605-595 · Cited by 307
Chemosensitization of tumors by resveratrol
Gupta, S. C., Kannappan, R., Reuter, S., Kim, J. H., & Aggarwal, B. B. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05852.x · Cited by 305
STAT proteins as novel targets for cancer drug discovery
Turkson, J. (2004) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.8.5.409 · Cited by 295
Self-citationIndirubin derivatives inhibit Stat3 signaling and induce apoptosis in human cancer cells
Nam, S., Buettner, R., Turkson, J., Kim, D., Cheng, J. Q., Muehlbeyer, S., Hippe, F., Vatter, S., Merz, K.-H., Eisenbrand, G., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409467102 · Cited by 294
Self-citationMolecular Pathways: JAK/STAT Pathway: Mutations, Inhibitors, and Resistance
Quintás-Cardama, A., & Verstovsek, S. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0284 · Cited by 284
Nelson, E. A., Walker, S. R., Weisberg, E., Bar-Natan, M., Barrett, R., Gashin, L. B., Terrell, S., Klitgaard, J. L., Santo, L., Addorio, M. R., et al. (2011) · Blood · doi:10.1182/blood-2009-11-255232 · Cited by 280
Targeting Stat3 in cancer therapy
Jing, N., & Tweardy, D. J. (2005) · Anti-Cancer Drugs · doi:10.1097/00001813-200507000-00002 · Cited by 278
Turkson, J., Kim, J. S., Zhang, S., Yuan, J., Huang, M., Glenn, M., Haura, E., Sebti, S., Hamilton, A. D., & Jove, R. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.261.3.3 · Cited by 255
Self-citationHonda, T., Rounds, B. V., Bore, L., Finlay, H. J., Favaloro, Suh, N., Wang, Y., Sporn, M. B., & Gribble, G. W. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm0002230 · Cited by 241
Pathak, A. K., Bhutani, M., Nair, A. S., Ahn, K. S., Chakraborty, A., Kadara, H., Guha, S., Sethi, G., & Aggarwal, B. B. (2007) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-06-0348 · Cited by 235
Lin, L., Hutzen, B., Zuo, M., Ball, S., Deangelis, S., Foust, E., Pandit, B., Ihnat, M. A., Shenoy, S. S., Kulp, S., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2468 · Cited by 234
Chitnis, T., Najafian, N., Benou, C., Salama, A. D., Grusby, M. J., Sayegh, M. H., & Khoury, S. J. (2001) · Journal of Clinical Investigation · doi:10.1172/jci12563 · Cited by 229
Yang, C.-L., Liu, Y.-Y., Ma, Y.-G., Xue, Y.-X., Liu, D.-G., Ren, Y., Liu, X.-B., Li, Y., & Li, Z. (2012) · PLoS ONE · doi:10.1371/journal.pone.0037960 · Cited by 220
Song, L., Morris, M., Bagui, T., Lee, F. Y., Jove, R., & Haura, E. B. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4620 · Cited by 204
Li, F., Fernandez, P. P., Rajendran, P., Hui, K. M., & Sethi, G. (2010) · Cancer Letters · doi:10.1016/j.canlet.2009.12.003 · Cited by 201
Th1 versus Th17: Are T cell cytokines relevant in multiple sclerosis?
Lovett-Racke, A. E., Yang, Y., & Racke, M. K. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2010.05.012 · Cited by 201
Nifuroxazide inhibits survival of multiple myeloma cells by directly inhibiting STAT3
Nelson, E. A., Walker, S. R., Kepich, A., Gashin, L. B., Hideshima, T., Ikeda, H., Chauhan, D., Anderson, K. C., & Frank, D. A. (2008) · Blood · doi:10.1182/blood-2007-12-129718 · Cited by 200
IL-4 Regulates Skin Homeostasis and the Predisposition toward Allergic Skin Inflammation
Sehra, S., Yao, Y., Howell, M. D., Nguyen, E. T., Kansas, G. S., Leung, D. Y. M., Travers, J. B., & Kaplan, M. H. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0901860 · Cited by 195
Siddiquee, K. A. Z., Gunning, P. T., Glenn, M., Katt, W. P., Zhang, S., Schroeck, C., Sebti, S. M., Jove, R., Hamilton, A. D., & Turkson, J. (2007) · ACS Chemical Biology · doi:10.1021/cb7001973 · Cited by 187
Self-citationDong, Y., Lu, B., Zhang, X., Zhang, J., Lai, L., Li, D., Wu, Y., Song, Y., Luo, J., Pang, X., et al. (2010) · Carcinogenesis · doi:10.1093/carcin/bgq167 · Cited by 180
Zhang, X., Yue, P., Fletcher, S., Zhao, W., Gunning, P. T., & Turkson, J. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.01.001 · Cited by 179
Self-citationSong, L., Rawal, B., Nemeth, J. A., & Haura, E. B. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0502 · Cited by 177
Li, F., Rajendran, P., & Sethi, G. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00874.x · Cited by 176
Interleukin-13 Augments Bronchial Smooth Muscle Contractility with an Up-Regulation of RhoA Protein
Chiba, Y., Nakazawa, S., Todoroki, M., Shinozaki, K., Sakai, H., & Misawa, M. (2009) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2008-0162oc · Cited by 173
Tu, S. P., Jin, H., Shi, J. D., Zhu, L. M., Suo, Y., Lu, G., Liu, A., Wang, T. C., & Yang, C. S. (2012) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-11-0247 · Cited by 165
Tai, W.-T., Cheng, A.-L., Shiau, C.-W., Huang, H.-P., Huang, J.-W., Chen, P.-J., & Chen, K.-F. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2011.01.047 · Cited by 158
Targeting Stat3 Abrogates EGFR Inhibitor Resistance in Cancer
Sen, M., Joyce, S., Panahandeh, M., Li, C., Thomas, S. M., Maxwell, J., Wang, L., Gooding, W. E., Johnson, D. E., & Grandis, J. R. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0792 · Cited by 158
Rajendran, P., Li, F., Shanmugam, M. K., Kannaiyan, R., Goh, J. N., Wong, K. F., Wang, W., Khin, E., Tergaonkar, V., Kumar, A. P., et al. (2012) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-11-0420 · Cited by 158
Kuperman, D. A., & Schleimer, R. P. (2008) · Current Molecular Medicine · doi:10.2174/156652408785161032 · Cited by 157
Jung, J. E., Kim, H. S., Lee, C. S., Park, D.-H., Kim, Y.-N., Lee, M.-J., Lee, S. E., Park, J., Kim, M.-S., Ye, S. K., et al. (2007) · Carcinogenesis · doi:10.1093/carcin/bgm130 · Cited by 154
Discovery of Chromone‐Based Inhibitors of the Transcription Factor STAT5
Müller, J., Sperl, B., Reindl, W., Kiessling, A., & Berg, T. (2008) · ChemBioChem · doi:10.1002/cbic.200700701 · Cited by 153
Shanmugam, M. K., Rajendran, P., Li, F., Nema, T., Vali, S., Abbasi, T., Kapoor, S., Sharma, A. K., Kumar, A. P., Ho, P. C., et al. (2011) · Journal of Molecular Medicine · doi:10.1007/s00109-011-0746-2 · Cited by 153
Lin, L., Deangelis, S., Foust, E., Fuchs, J. R., Li, C., Li, P., Schwartz, E. B., Lesinski, G. B., Benson, D., Lü, J., et al. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-217 · Cited by 152
Identification of a New Series of STAT3 Inhibitors by Virtual Screening
Matsuno, K., Masuda, Y., Uehara, Y., Satō, H., Muroya, A., Takahashi, O., Yokotagawa, T., Furuya, T., Okawara, T., Otsuka, M., et al. (2010) · ACS Medicinal Chemistry Letters · doi:10.1021/ml1000273 · Cited by 150
Rajendran, P., Li, F., Shanmugam, M. K., Vali, S., Abbasi, T., Kapoor, S., Ahn, K. S., Kumar, A. P., & Sethi, G. (2011) · Journal of Cellular Physiology · doi:10.1002/jcp.22954 · Cited by 149
Pedranzini, L., Dechow, T. N., Berishaj, M., Comenzo, R. L., Zhou, P., Azare, J., Bornmann, W. G., & Bromberg, J. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4280 · Cited by 149
Zhang, X., Sun, Y., Pireddu, R., Yang, H., Urlam, M. K., Lawrence, H. R., Guida, W. C., Lawrence, N. J., & Sebti, S. M. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3175 · Cited by 149
Yang, Y., Chang, Y., Huang, P., Chiou, G., Tseng, L., Chiou, S., Chen, M., Chen, M., Shih, Y., Chang, C., et al. (2011) · Journal of Cellular Physiology · doi:10.1002/jcp.22806 · Cited by 148
Lee, J., Hahm, E., & Singh, S. V. (2010) · Carcinogenesis · doi:10.1093/carcin/bgq175 · Cited by 147
Targeting Signal Transducer and Activator of Transcription Signaling Pathway in Leukemias
Beneklı, M., Baumann, H., & Wetzler, M. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.3264 · Cited by 141
Li, W.-C., Ye, S., Sun, R., Liu, Y., Tang, Z., Kim, Y., Karras, J. G., & Zhang, H. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0484 · Cited by 141
Coleman, Ren, Z., Mandal, P. K., Cameron, A. G., Dyer, G. A., Muranjan, S., Campbell, M. L., Chen, X., & McMurray, J. S. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm050513m · Cited by 141
Stat5a is tyrosine phosphorylated and nuclear localized in a high proportion of human breast cancers
Cotarla, I., Ren, S. V., Zhang, Y., Gehan, E. A., Singh, B., & Furth, P. A. (2003) · International Journal of Cancer · doi:10.1002/ijc.11619 · Cited by 139
Kannaiyan, R., Hay, H. S., Rajendran, P., Li, F., Shanmugam, M. K., Vali, S., Abbasi, T., Kapoor, S., Sharma, A. K., Kumar, A. P., et al. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01449.x · Cited by 138
Chemical Probes that Competitively and Selectively Inhibit Stat3 Activation
Xu, X., Kasembeli, M. M., Jiang, X., Tweardy, B. J., & Tweardy, D. J. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004783 · Cited by 138
BCR-ABL1-independent PI3Kinase activation causing imatinib-resistance
Quentmeier, H., Eberth, S., Romani, J., Zaborski, M., & Drexler, H. G. (2011) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-4-6 · Cited by 136
The IL-4/IL-13/Stat6 signalling pathway promotes luminal mammary epithelial cell development
Khaled, W. T., Read, E. K. C., Nicholson, S. E., Baxter, F. O., Brennan, A. J., Came, P. J., Sprigg, N. S., McKenzie, A. N. J., & Watson, C. J. (2007) · Development · doi:10.1242/dev.003194 · Cited by 135
Rajendran, P., Li, F., Manu, K. A., Shanmugam, M. K., Loo, S. Y., Kumar, A. P., & Sethi, G. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.01187.x · Cited by 132
A Novel STAT6 Inhibitor AS1517499 Ameliorates Antigen-Induced Bronchial Hypercontractility in Mice
Chiba, Y., Todoroki, M., Nishida, Y., Tanabe, M., & Misawa, M. (2009) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2008-0163oc · Cited by 130
Mandal, P. K., Gao, F., Lü, Z., Ren, Z., Ramesh, R., Birtwistle, J. S., Kaluarachchi, K., Chen, X., Bast, R. C., Liao, W. S. ‐., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm2000882 · Cited by 130
Identification of a High-Affinity Phosphopeptide Inhibitor of Stat3
Ren, Z., Cabell, L. A., Schaefer, T. S., & McMurray, J. S. (2003) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(02)01050-8 · Cited by 128
Muto, A., Hori, M., Sasaki, Y., Saitoh, A., Yasuda, I., Maekawa, T., Uchida, T., Asakura, K., Nakazato, T., Kaneda, T., et al. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0605 · Cited by 126
Auranofin blocks interleukin‐6 signalling by inhibiting phosphorylation of JAK1 and STAT3
Kim, N.-H., Lee, M.-Y., Park, S.-J., Choi, J.-S., Oh, M.-K., & Kim, I.-S. (2007) · Immunology · doi:10.1111/j.1365-2567.2007.02679.x · Cited by 125
Gamma interferon: a central mediator in atherosclerosis
León, M. L. A., & Zuckerman, S. H. (2005) · Inflammation Research · doi:10.1007/s00011-005-1377-2 · Cited by 125
Yang, F., Brown, C. E., Buettner, R., Hedvat, M., Starr, R., Scuto, A., Schroeder, A., Jensen, M. C., & Jove, R. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0947 · Cited by 121
Looyenga, B. D., Hutchings, D., Cherni, I., Kingsley, C., Weiss, G. J., & MacKeigan, J. P. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030820 · Cited by 120
Kim, M., Nam, H.-J., Kim, H., Han, S., Im, S., Kim, T., Oh, D., & Bang, Y. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.02.010 · Cited by 118
Kim, S., Kim, H., Kim, Y., Oh, D., Im, S., Lee, D., Jong, H.-S., Kim, T., & Bang, Y. (2008) · International Journal of Oncology · doi:10.3892/ijo.32.1.89 · Cited by 118
Santandreu, F. M., Valle, A., Oliver, J., & Roca, P. (2011) · Cellular Physiology and Biochemistry · doi:10.1159/000331733 · Cited by 115
Antiangiogenic and Antimetastatic Activity of JAK Inhibitor AZD1480
Xin, H., Herrmann, A., Reckamp, K. L., Zhang, W., Pal, S. K., Hedvat, M., Zhang, C., Liang, W. P., Scuto, A., Weng, S., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1217 · Cited by 114
Hsu, H., Huang, P., Chang, Y., Tzao, C., Chen, Y., Shih, H., Hung, S., Chen, Y., Tseng, L., & Chiou, S. (2011) · Cancer · doi:10.1002/cncr.25869 · Cited by 113
Nam, S., Williams, A. H., Vultur, A., List, A. F., Bhalla, K. N., Smith, D. D., Lee, F. Y., & Jove, R. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0446 · Cited by 110
Pandey, M. K., Sung, B., & Aggarwal, B. B. (2009) · International Journal of Cancer · doi:10.1002/ijc.25059 · Cited by 108
Manshouri, T., Estrov, Z. E., Quintás‐Cardama, A., Burger, J. A., Zhang, Y., Livun, A., Knez, L., Harris, D., Creighton, C. J., Kantarjian, H. M., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-4002 · Cited by 106
Leeman‐Neill, R. J., Cai, Q., Joyce, S. C., Thomas, S. M., Bhola, N. E., Neill, D. B., Arbiser, J. L., & Grandis, J. R. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0333 · Cited by 106
Withaferin A inhibits JAK/STAT3 signaling and induces apoptosis of human renal carcinoma Caki cells
Um, H. J., Min, K., Kim, D., & Kwon, T. K. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.08.133 · Cited by 102
Structure-Based Design of Conformationally Constrained, Cell-Permeable STAT3 Inhibitors
Chen, J., Bai, L., Bernard, D., Nikolovska‐Coleska, Z., Gomez, C., Zhang, J., Han, Y., & Wang, S. (2010) · ACS Medicinal Chemistry Letters · doi:10.1021/ml100010j · Cited by 101
Agrawal, S., Febbraio, M., Podrez, E. A., Cathcart, M. K., Stark, G. R., & Chisolm, G. M. (2007) · Circulation · doi:10.1161/circulationaha.107.696922 · Cited by 98
McCusker, C. T., Wang, Y., Shan, J., Kinyanjui, M. W., Villeneuve, A., Michael, H., & Fixman, E. D. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.4.2556 · Cited by 96
Nakaya, A., Sagawa, M., Muto, A., Uchida, H., Ikeda, Y., & Kizaki, M. (2010) · Leukemia Research · doi:10.1016/j.leukres.2010.05.011 · Cited by 96
Fossey, S. L., Bear, M. D., Lin, J., Li, C., Schwartz, E. B., Li, P., Fuchs, J. R., Fenger, J. M., Kisseberth, W. C., & London, C. A. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-112 · Cited by 95
Yang, J., Cai, X., Lu, W., Hu, C., Xu, X., Yu, Q., & Cao, P. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.09.019 · Cited by 95
Chen, H., Yang, Z., Ding, C., Chu, L., Zhang, Y., Terry, K., Liu, H., Shen, Q., & Zhou, J. (2013) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2013.01.023 · Cited by 94
Fuh, B., Sobo, M., Cen, L., Josiah, D. T., Hutzen, B. J., Cisek, K. K., Bhasin, D. K., Regan, N., Lin, L., Chan, C., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6604793 · Cited by 94
Zhang, X., Song, Y., Wu, Y., Dong, Y., Lai, L., Zhang, J., Lu, B., Dai, F., He, L., Liu, M., et al. (2011) · International Journal of Cancer · doi:10.1002/ijc.25909 · Cited by 89
Blockade of STAT3 activation by sorafenib derivatives through enhancing SHP-1 phosphatase activity
Chen, K., Tai, W., Hsu, C.-Y., Huang, J., Liu, C., Chen, P., Kim, I., & Shiau, C. (2012) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2012.07.023 · Cited by 89
Therapeutic Potential of AZD1480 for the Treatment of Human Glioblastoma
McFarland, B. C., Ma, J., Langford, C. P., Gillespie, G. Y., Yu, H., Zheng, Y., Nozell, S. E., Huszar, D., & Benveniste, E. N. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0480 · Cited by 89
Atiprimod blocks STAT3 phosphorylation and induces apoptosis in multiple myeloma cells
Amit-Vazina, M., Shishodia, S., Harris, D., Van, Q., Wang, M., Weber, D., Alexanian, R., Talpaz, M., Aggarwal, B. B., & Estrov, Z. E. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602637 · Cited by 86
Niflumic Acid Suppresses Interleukin-13–induced Asthma Phenotypes
Nakano, T., Inoue, H., Fukuyama, S., Matsumoto, K., Matsumura, M., Tsuda, M., Matsumoto, T., Aizawa, H., & Nakanishi, Y. (2006) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200410-1420oc · Cited by 86
Nam, S., Xie, J., Perkins, A., Ma, Y., Yang, F., Wu, J., Wang, Y., Xu, R.-Z., Huang, W., Horne, D. A., et al. (2012) · Molecular Oncology · doi:10.1016/j.molonc.2012.05.002 · Cited by 85
Bill, M. A., Nicholas, C., Mace, T. A., Etter, J. P., Li, C., Schwartz, E. B., Fuchs, J. R., Young, G. S., Lin, L., Lin, J., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040724 · Cited by 84
Inhibitory effect of cucurbitacin E on pancreatic cancer cells growth via STAT3 signaling
Sun, C., Zhang, M., Shan, X., Zhou, X., Jiao, Y., Wang, Y., Li‐Ling, J., & Deng, Y. (2009) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-009-0698-x · Cited by 83
Liu, T., Peng, H., Zhang, M., Deng, Y., & Zheng-hu, W. (2010) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2010.04.062 · Cited by 82
Grávalos, C., Gómez-Martín, C., Rivera, F., Alés, I., Queralt, B., Márquez, A., Jiménez, U., Alonso, V., García‐Carbonero, R., Sastre, J., et al. (2011) · Clinical & Translational Oncology · doi:10.1007/s12094-011-0637-6 · Cited by 80
Arbiser, J. L., Govindarajan, B., Battle, T. E., Lynch, R. A., Frank, D. A., Ushio‐Fukai, M., Perry, B. N., Stern, D. F., Bowden, G. T., Liu, A., et al. (2006) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5700276 · Cited by 78
Burel, S. A., Han, S.-R., Lee, H.-S., Norris, D. A., Lee, B., Machemer, T., Park, S., Zhou, T., He, G., Kim, Y., et al. (2013) · Nucleic Acid Therapeutics · doi:10.1089/nat.2013.0422 · Cited by 77
Nelson, E. A., Sharma, S. V., Settleman, J. E., & Frank, D. A. (2011) · Oncotarget · doi:10.18632/oncotarget.296 · Cited by 76
Nam, S., Wen, W. X., Schroeder, A., Herrmann, A., Yu, H., Cheng, X., Merz, K., Eisenbrand, G., Li, H., Yuan, Y., et al. (2012) · Molecular Oncology · doi:10.1016/j.molonc.2012.10.013 · Cited by 75
Duan, Z., Ames, R. Y., Ryan, M. B., Hornicek, F. J., Mankin, H. J., & Seiden, M. V. (2008) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-008-0785-8 · Cited by 75
Nam, S., Scuto, A., Yang, F., Chen, W., Park, S., Yoo, H., Koenig, H., Bhatia, R., Cheng, X., Merz, K., et al. (2012) · Molecular Oncology · doi:10.1016/j.molonc.2012.02.002 · Cited by 75
STAT2 Contributes to Promotion of Colorectal and Skin Carcinogenesis
Gamero, A. M., Young, M. R., Mentor-Marcel, R. A., Bobe, G., Scarzello, A. J., Wise, J., & Colburn, N. H. (2010) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-09-0105 · Cited by 75
Zhao, W. M., Jaganathan, S., & Turkson, J. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.154088 · Cited by 74
Self-citationInhibition of Stat3 activation by sanguinarine suppresses prostate cancer cell growth and invasion
Sun, M., Liu, C., Nadiminty, N., Lou, W., Zhu, Y., Yang, J. C., Evans, C. P., Zhou, Q., & Gao, A. C. (2011) · The Prostate · doi:10.1002/pros.21409 · Cited by 72
Ren, Y., Lü, L., Guo, T. B., Qiu, J., Yang, Y., Liu, A., & Zhang, J. Z. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.2.1491 · Cited by 70
Leeman‐Neill, R. J., Seethala, R. R., Singh, S. V., Freilino, M. L., Bednash, J. S., Thomas, S. M., Panahandeh, M. C., Gooding, W. E., Joyce, S. C., Lingen, M. W., et al. (2010) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-10-0249 · Cited by 70
Kang, C. (1992) · International Journal of Oncology · doi:10.3892/ijo_00000125 · Cited by 70
Chen, X., Du, Y., Jing, N., Zhang, X., Qin, X., Wang, Y., Hou, J., Wang, Q. L., & Yang, J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0063697 · Cited by 69
Sai, K., Wang, S., Balasubramaniyan, V., Conrad, C. A., Lang, F. F., Aldape, K., Szymański, S., Fokt, I., Dasgupta, A., Madden, T. L., et al. (2012) · Journal of Neuro-Oncology · doi:10.1007/s11060-011-0786-z · Cited by 69
Selvendiran, K., Ahmed, S., Dayton, A., Kuppusamy, M. L., Rivera, B. K., Kálai, T., Hideg, K., & Kuppusamy, P. (2011) · Cancer Biology & Therapy · doi:10.4161/cbt.12.9.17713 · Cited by 68
Badr, G., Mohany, M., & Abu-Tarboush, F. (2011) · Lipids in Health and Disease · doi:10.1186/1476-511x-10-236 · Cited by 68
Walker, S. R., Chaudhury, M., Nelson, E. A., & Frank, D. A. (2010) · Molecular Pharmacology · doi:10.1124/mol.110.066316 · Cited by 68
Onimoe, G., Liu, A., Lin, L., Wei, C., Schwartz, E. B., Bhasin, D. K., Li, C., Fuchs, J. R., Li, P., Houghton, P. J., et al. (2011) · Investigational New Drugs · doi:10.1007/s10637-011-9645-1 · Cited by 67
Lui, V. W. Y., Boehm, A. L., Koppikar, P., Leeman‐Neill, R. J., Johnson, D. E., Ogagan, M. J., Childs, E. E., Freilino, M. L., & Grandis, J. R. (2007) · Molecular Pharmacology · doi:10.1124/mol.106.032284 · Cited by 67
The JAK inhibitor AZD1480 regulates proliferation and immunity in Hodgkin lymphoma
Derenzini, E., Lemoine, M., Buglio, D., Katayama, H., Ji, Y., Davis, R. E., Sen, S., & Younes, A. (2011) · Blood Cancer Journal · doi:10.1038/bcj.2011.46 · Cited by 67
Buitenhuis, M., Baltus, B., Lammers, J. J., Coffer, P. J., & Koenderman, L. (2002) · Blood · doi:10.1182/blood-2002-03-0740 · Cited by 66
Lisowski, M., & Bednarczyk, M. F. (2005) · Folia Biologica · doi:10.3409/1734916054663465 · Cited by 65
Lin, C.-L., Chen, R., Chen, J. Y., Chu, Y.-C., Wang, H., Chou, H.-L., Chang, W., Fong, Y., Chang, W., Wu, C.-Y., et al. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms13056236 · Cited by 64
Dave, B., Landis, M. D., Dobrolecki, L. E., Wu, M.-F., Zhang, X., Westbrook, T. F., Hilsenbeck, S. G., Liu, D., Lewis, M. T., Tweardy, D. J., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030207 · Cited by 63
Transcription Protein STAT1: Biology and Relation to Cancer
Adámková, L., Součková, K., & Kovařík, J. (2007) · Folia Biologica · doi:10.14712/fb2007053010001 · Cited by 62
Ryu, K., Susa, M., Choy, E., Cao, Y., Hornicek, F. J., Mankin, H. J., & Duan, Z. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-187 · Cited by 61
Kim, J., Kim, H. S., Shin, Y., Lee, C. S., Won, C., Lee, S.-A., Lee, S. E., Kim, Y., Kang, J., Ye, S., et al. (2008) · Experimental & Molecular Medicine · doi:10.3858/emm.2008.40.5.514 · Cited by 60
Lee, B., Kim, Y.-J., Cho, D., Sohn, N., & Kang, H. G. (2011) · Immunopharmacology and Immunotoxicology · doi:10.3109/08923973.2011.564185 · Cited by 60
Bachawal, S. V., Wali, V. B., & Sylvester, P. W. (2010) · PubMed · Cited by 60
Tseng, L., Huang, P., Chen, Y.-R., Chen, Y., Chou, Y.-C., Chen, Y., Chang, Y.-L., Hsu, H., Lan, Y., Chen, K.-H., et al. (2012) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.188730 · Cited by 60
Buss, J. E., & Marsters, J. C. (1995) · Chemistry & Biology · doi:10.1016/1074-5521(95)90083-7 · Cited by 57
Barton, B. E., Murphy, T. F., Shu, P., Huang, H. F. S., Meyenhofen, M., & Barton, A. B. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1183.3.10 · Cited by 55
Gunning, P. T., Katt, W. P., Glenn, M. P., Siddiquee, K., Kim, J. S., Jove, R., Sebti, S. M., Turkson, J., & Hamilton, A. D. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.01.077 · Cited by 53
Self-citationLack of toxicity of a STAT3 decoy oligonucleotide
Sen, M., Tosca, P. J., Zwayer, C., Ryan, M. J., Johnson, J. D., Knostman, K. A. B., Giclas, P. C., Peggins, J. O., Tomaszewski, J. E., McMurray, T. P., et al. (2009) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-008-0823-6 · Cited by 53
Inhibition of p-STAT3 Enhances IFN-α Efficacy against Metastatic Melanoma in a Murine Model
Kong, L.-Y., Gelbard, A. H., Wei, J., Reina-Ortiz, C., Wang, Y., Yang, E. C. C., Hailemichael, Y., Fokt, I., Jayakumar, A., Qiao, W., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0279 · Cited by 53
Anti-Angiogenic Activity of a Small Molecule STAT3 Inhibitor LLL12
Bid, H. K., Oswald, D. J., Li, C., London, C. A., Lin, J., & Houghton, P. J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0035513 · Cited by 52
Liu, S., Wang, K.-B., Lan, K., Lee, W. J., Pan, H. C., Wu, S., Peng, Y. C., Chen, Y. C., Shen, C. C., Cheng, H., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0043711 · Cited by 51
Novel 7H-pyrrolo[2,3-d]pyrimidine derivatives as potent and orally active STAT6 inhibitors
Nagashima, S., Hondo, T., Nagata, H., Ogiyama, T., Maeda, J., Hoshii, H., Kontani, T., Kuromitsu, S., Ohga, K., Orita, M., et al. (2009) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2009.08.021 · Cited by 51
Zhang, C., Li, B., Gaikwad, A. S., Haridas, V., Xu, Z., Gutterman, J. U., & Duvic, M. A. (2008) · Journal of Investigative Dermatology · doi:10.1038/jid.2008.138 · Cited by 49
Akiyama (2011) · International Journal of Oncology · doi:10.3892/ijo.2011.957 · Cited by 49
Hückel, M., Schurigt, U., Wagner, A. H., Stöckigt, R., Petrow, P. K., Thoss, K., Gajda, M. R., Henzgen, S., Hecker, M., & Bräuer, R. (2005) · Arthritis Research & Therapy · doi:10.1186/ar1869 · Cited by 48
Weinmann‐Menke, J., Bork, T., Kutska, B., Byrne, K. T., Blanfeld, M., Relle, M., Kelley, V. R., & Schwarting, A. (2010) · Kidney International · doi:10.1038/ki.2010.438 · Cited by 47
Tran, K., Risingsong, R., Royce, D. B., Williams, C. R., Sporn, M. B., & Liby, K. T. (2012) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-11-0404 · Cited by 47
Auzenne, E. J., Klostergaard, J., Mandal, P. K., Liao, W. S. ‐., Lü, Z., Gao, F., Bast, R. C., Robertson, F. M., & McMurray, J. S. (2012) · PubMed · Cited by 47
Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of NSCLC
Pallis, A. G., & Syrigos, K. N. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2012.12.025 · Cited by 44
Faderl, S. H., Ferrajoli, A., Harris, D., Van, Q., Kantarjian, H. M., & Estrov, Z. E. (2006) · Leukemia Research · doi:10.1016/j.leukres.2006.05.027 · Cited by 43
Tierney, B. J., McCann, G. A.-L., Cohn, D. E., Eisenhauer, E., Sudhakar, M., Kuppusamy, P., Hideg, K., & Selvendiran, K. (2012) · Cancer Biology & Therapy · doi:10.4161/cbt.20559 · Cited by 43
Souissi, I., Ladam, P., Cognet, J. A. H., Coquil, S. L., Varin‐Blank, N., Baran‐Marszak, F., Metelev, V., & Fagard, R. (2012) · Molecular Cancer · doi:10.1186/1476-4598-11-12 · Cited by 43
Chapoval, S. P., Dasgupta, P., Smith, E., DeTolla, L. J., Lipsky, M. M., Kelly-Welch, A. E., & Keegan, A. D. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1002567 · Cited by 42
Saturnino, C., Palladino, C., Napoli, M., Sinicropi, M. S., Botta, A., Sala, M., de Prati, A. C., Novellino, E., & Suzuki, H. (2012) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2012.11.004 · Cited by 40
Evaluation of anti-leukemia effect of resveratrol by modulating SATA3 signaling
Li, T., Wang, W., Chen, H., Li, T., & Lu, Y. (2009) · International Immunopharmacology · doi:10.1016/j.intimp.2009.09.009 · Cited by 40
Role of Stat3 in Skin Carcinogenesis: Insights Gained from Relevant Mouse Models
Macias, E., Rao, D., & DiGiovanni, J. (2013) · Journal of Skin Cancer · doi:10.1155/2013/684050 · Cited by 40
Chang, C. J., Chiang, C.-H., Song, W.-S., Tsai, S. K., Woung, L., Chang, C. H., Jeng, S.-Y., Tsai, C. Y., Hsu, C. C., Lee, H. F., et al. (2012) · Child s Nervous System · doi:10.1007/s00381-011-1672-x · Cited by 39
Role of Th1 and Th2 cells in autoimmune demyelinating disease
Nagelkerken, L. M. (1998) · Brazilian Journal of Medical and Biological Research · doi:10.1590/s0100-879x1998000100007 · Cited by 39
Discovery of the catechol structural moiety as a Stat3 SH2 domain inhibitor by virtual screening
Hao, W., Hu, Y., Niu, C., Huang, X., Chang, C.-P. B., Gibbons, J. J., & Xu, J. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.08.032 · Cited by 37
Structural basis for the binding of high affinity phosphopeptides to Stat3
McMurray, J. S. (2007) · Biopolymers · doi:10.1002/bip.20901 · Cited by 36
Inhibitory effects of decoy-ODN targeting activated STAT3 on human glioma growth in vivo.
Shen, J., Li, R., & Li, G. (2009) · PubMed · Cited by 36
Liu, L., Kritsanida, M., Magiatis, P., Gaboriaud‐Kolar, N., Wang, Y., Wu, J., Buettner, R., Yang, F., Nam, S., Skaltsounis, A., et al. (2012) · Cancer Biology & Therapy · doi:10.4161/cbt.21781 · Cited by 35
Wang, X., Zeng, J., Shi, M., Zhao, S. Y., Bai, W. L., Cao, W., Tu, Z., Huang, Z.-G., & Feng, W. (2010) · DNA and Cell Biology · doi:10.1089/dna.2010.1112 · Cited by 35
Wang, Y., Li, Y., Shan, J., Fixman, E. D., & McCusker, C. T. (2011) · Clinical & Experimental Allergy · doi:10.1111/j.1365-2222.2011.03853.x · Cited by 34
Stadlbauer, T. H. W., Wagner, A. H., Hölschermann, H., Fiedel, S., Fingerhuth, H., Tillmanns, H., Bohle, R. M., & Hecker, M. (2008) · Cardiovascular Research · doi:10.1093/cvr/cvn135 · Cited by 34
TMC-264, a Novel Inhibitor of STAT6 Activation Produced by Phoma sp. TC 1674
Sakurai, M., NISHIO, M., Yamamoto, K., Okuda, T., Kawano, K., & Ohnuki, T. (2003) · The Journal of Antibiotics · doi:10.7164/antibiotics.56.513 · Cited by 32
Yang, F., Jové, V., Buettner, R., Xin, H., Wu, J., Wang, Y., Nam, S., Xu, Y., Ara, T., DeClerck, Y. A., et al. (2012) · Cancer Biology & Therapy · doi:10.4161/cbt.19603 · Cited by 30
Inhibitory effects of the JAK inhibitor CP690,550 on human CD4+ T lymphocyte cytokine production
Migita, K., Miyashita, T., Izumi, Y., Koga, T., Komori, A., Maeda, Y., Jiuchi, Y., Aiba, Y., Yamasaki, S., Kawakami, A., et al. (2011) · BMC Immunology · doi:10.1186/1471-2172-12-51 · Cited by 29
Kandala (2012) · Drug Discoveries & Therapeutics · doi:10.5582/ddt.2012.v6.2.94 · Cited by 26
Stolzenberger, S., Haake, M., & Duschl, A. (2001) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.2001.02417.x · Cited by 25
STAT6 phosphorylation inhibitors block eotaxin-3 secretion in bronchial epithelial cells
Zhou, L., Kawate, T., Liu, X., Kim, Y. B., Zhao, Y., Feng, G., Banerji, J., Nash, H. M., Whitehurst, C. E., Jindal, S., et al. (2011) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2011.12.006 · Cited by 24
Cited by
The JAK/STAT signaling pathway: from bench to clinic
Hu, X., li, J., Fu, M., Zhao, X., & Wang, W. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00791-1 · Cited by 2,633
Karki, R., Sharma, B. R., Tuladhar, S., Williams, E. P., Zalduondo, L., Samir, P., Zheng, M., Sundaram, B., Banoth, B., Malireddi, R. K. S., et al. (2021) · Cell · doi:10.1016/j.cell.2020.11.025 · Cited by 1,734
Mechanisms and consequences of Jak–STAT signaling in the immune system
Villarino, A. V., Kanno, Y., & O'Shea, J. J. (2017) · Nature Immunology · doi:10.1038/ni.3691 · Cited by 1,221
Interleukin-6: designing specific therapeutics for a complex cytokine
Garbers, C., Heink, S., Korn, T., & Rose-John, S. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.45 · Cited by 643
JAK–STAT pathway targeting for the treatment of inflammatory bowel disease
Salas, A., Hernandez-Rocha, C., Duijvestein, M., Faubion, W., McGovern, D., Vermeire, S., Vetrano, S., & Vande Casteele, N. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-0273-0 · Cited by 635
Metadata
- Authors
- Miklossy, G., Hilliard, T. S., & Turkson, J.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2013-08
- Volume
- 12
- Issue
- 8
- Pages
- 611-629
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2034038847
- Cited by
- 413
- References
- 208
- FWCI
- 2.94
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.